Articles by Katie Kosko
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
Imlunestrant plus abemaciclib improved PFS across subgroups in ER+/HER2- breast cancer, per EMBER-3 data.
Abemaciclib plus fulvestrant showed benefit across biomarkers after CDK4/6i failure in advanced HR+/HER2- breast cancer.
T-DXd improved PFS and response rates vs chemo in HR+/HER2-low or -ultralow metastatic breast cancer in DESTINY-Breast06.
Emiltatug ledadotin showed early clinical activity and was well tolerated in heavily pretreated patients with TNBC.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Ribociclib plus ET shows similar pCR rates to chemo in intermediate-risk HR+/HER2– early breast cancer, per WSG ADAPTcycle.
Several genetically predicted environmental factors increase the risk of IgAN and membranous nephropathy, a study found.
Higher fat mass and lower fat density linked to increased T-DXd dose reductions and toxicity in metastatic breast cancer.
Pembrolizumab plus dual HER2 blockade may offer a chemo-free option for early HER2+ breast cancer, phase 2 data suggest.
The phase 3 global, multi-center trial included 492 patients with stage IV NSCLC.
Nivolumab plus ipilimumab with chemotherapy also helped patients with brain metastases live longer versus chemotherapy alone.
Researchers used data from the Thoracic Tumors Registry to conduct 2 analyses using artificial intelligence.
The intervention included psychoeducation, relaxation training, and behavioral techniques for managing acute breathlessness.
Researchers addressed the limited data comparing relative outcomes among osimertinib, afatinib, and erlotinib.
The analysis supplements the primary report and shows that selpercatinib may prevent the formation of new CNS metastases.
Researchers uncovered an association between survival and intratumoral Escherichia in patients receiving certain therapies.
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
The study included patients who had received a diagnosis of stage IIA-III unresectable NSCLC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.